A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004747-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Main Objective: To evaluate the percentage of patients with curatively unresectable MPNST who have achieved clinical response; complete response (CR), partial response (PR), or stable disease (SD) at 18 weeks as assessed by the Investigator, by using RECIST, v1.1.


Critère d'inclusion

  • Malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery

Liens